<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03552991</url>
  </required_header>
  <id_info>
    <org_study_id>Agio study</org_study_id>
    <nct_id>NCT03552991</nct_id>
  </id_info>
  <brief_title>Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bukwang Pharmaceutical, Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ChunLab, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of a commercial dietary fiber supplement
      on patients with type 2 diabetes mellitus, in the way of glucose control, insulin action in
      the body, and the gut microbiota (bacteria) abundance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fiber supplements such as psyllium are known to be beneficial to glycemic control in patients
      with type 2 diabetes mellitus (T2DM). Gut microbiota has a role in regulating host energy
      metabolism and systemic inflammation by several pathways such as short-chain fatty acid
      production, fasting-induced adipose factor expression, endocannabinoid system, and gut
      epithelial permeability. As dietary components can influence the composition of the
      microbiota, we hypothesized that fiber supplements could modify gut microbiota and
      consequently affect glycemic control and inflammatory condition in patients with T2DM.

      The primary outcome was to assess the effect of fiber on glucose control (by comparing
      fasting glucose and glycoalbumin), insulin secretion and sensitivity. Secondary outcomes were
      the changes abundance of microbiota, incretins, and lipopolysaccharide (LPS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>the 4th week of study</time_frame>
    <description>By comparing the level of 4th week, compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycoalbumin</measure>
    <time_frame>the 4th week of study</time_frame>
    <description>By comparing the level of 4th week, compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulinogenic index</measure>
    <time_frame>the 4th week of study</time_frame>
    <description>By comparing the level of 4th week, compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative insulin sensitivity check index (QUICKI)</measure>
    <time_frame>the 4th week of study</time_frame>
    <description>By comparing the level of 4th week, compared to baseline. QUICKI is derived from fasting blood glucose and insulin level, reflecting insulin sensitivity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiota composition change</measure>
    <time_frame>the 4th week of study</time_frame>
    <description>By comparing the level of 4th week, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incretins (GIP)</measure>
    <time_frame>the 4th week of study</time_frame>
    <description>By comparing the level of 4th week, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incretins (GLP-1)</measure>
    <time_frame>the 4th week of study</time_frame>
    <description>By comparing the level of 4th week, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incretins (GLP-2)</measure>
    <time_frame>the 4th week of study</time_frame>
    <description>By comparing the level of 4th week, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipopolysaccharide (LPS)</measure>
    <time_frame>the 4th week of study</time_frame>
    <description>By comparing the level of 4th week, compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Agio arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>It is a pilot study based on the proof-of-concept that dietary fiber helps glucose control in patients with type 2 diabetes. As a single-arm study, 'Agiocur Pregranules' (dietary fiber) is administered for 28 days and stopped for next 28 days, in patients with type 2 diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Agiocur Pregranules</intervention_name>
    <description>6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout</description>
    <arm_group_label>Agio arm</arm_group_label>
    <other_name>Agio gran.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all of the followings):

          -  Among type 2 diabetic patients who visit Diabetes Center at Samsung Medical Center

          -  2 or more of following are required:

               1. use of lipid-lowering drugs and / or triglyceride ≥ 150 mg/dL, high-density
                  lipoprotein &lt; 40 mg/dL in men and &lt; 50 mg/dL in women

               2. waist circumference &gt; 90 cm in men and &gt; 80 cm in women

               3. antihypertensive medication and / or blood pressure ≥ 130/85 mmHg

          -  Hemoglobin A1c level 7.0 - 9.0% (6.5 - 9.0% in age 50-60 years old)

          -  Patients who are treated with combination therapy of sulfonylurea and metformin at
             least 6 months and in steady-glucose-controlled state.

        Exclusion Criteria (at least one of the followings):

          -  Patients using insulin, alpha-glucosidase inhibitor, meglitinide, thiazolidinedione,
             or incretin agent (both oral or injectables)

          -  Recently diagnosed (within 6 months) acute diabetic complication such as diabetic
             ketoacidosis and hyperosmolar hyperglycemic state

          -  Clinically significant cardiovascular disease

          -  Patients treated with oral or intravenous antibiotics last 12 months

          -  Patients who took fiber supplements last 6 months

          -  Fasting serum c-peptide level &lt; 1 ng/mL

          -  Duration of type 2 diabetes &gt; 10 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Kim DJ. The epidemiology of diabetes in Korea. Diabetes Metab J. 2011 Aug;35(4):303-8. doi: 10.4093/dmj.2011.35.4.303. Epub 2011 Aug 31.</citation>
    <PMID>21977448</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim JH, Kim DJ, Jang HC, Choi SH. Epidemiology of micro- and macrovascular complications of type 2 diabetes in Korea. Diabetes Metab J. 2011 Dec;35(6):571-7. doi: 10.4093/dmj.2011.35.6.571. Epub 2011 Dec 26.</citation>
    <PMID>22247898</PMID>
  </results_reference>
  <results_reference>
    <citation>Slavin JL. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc. 2008 Oct;108(10):1716-31. Erratum in: J Am Diet Assoc. 2009 Feb;109(2):350.</citation>
    <PMID>18953766</PMID>
  </results_reference>
  <results_reference>
    <citation>Bajorek SA, Morello CM. Effects of dietary fiber and low glycemic index diet on glucose control in subjects with type 2 diabetes mellitus. Ann Pharmacother. 2010 Nov;44(11):1786-92. doi: 10.1345/aph.1P347. Epub 2010 Oct 19. Review.</citation>
    <PMID>20959501</PMID>
  </results_reference>
  <results_reference>
    <citation>Burcelin R, Serino M, Chabo C, Blasco-Baque V, Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol. 2011 Dec;48(4):257-273. doi: 10.1007/s00592-011-0333-6. Epub 2011 Oct 2. Review.</citation>
    <PMID>21964884</PMID>
  </results_reference>
  <results_reference>
    <citation>Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D, Stares MD, Scott P, Bergerat A, Louis P, McIntosh F, Johnstone AM, Lobley GE, Parkhill J, Flint HJ. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011 Feb;5(2):220-30. doi: 10.1038/ismej.2010.118. Epub 2010 Aug 5.</citation>
    <PMID>20686513</PMID>
  </results_reference>
  <results_reference>
    <citation>Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol. 2011 Jan;12(1):5-9. doi: 10.1038/ni0111-5.</citation>
    <PMID>21169997</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>June 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>June 10, 2018</last_update_submitted>
  <last_update_submitted_qc>June 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>MOON-KYU LEE</investigator_full_name>
    <investigator_title>Professor, Division of Endocrinology and Metabolism, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Dietary Fiber</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Metformin</keyword>
  <keyword>Sulfonylurea Compounds</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

